← Research library

Picamilon in stage I and II chronic cerebral ischemia: open comparative study

Observational study · 2025

What was studied
100 enrolled; 94 in per-protocol efficacy analysis; stage I and II groups initially 50 each
Main finding
In the 2025 open Picamilon comparison, MoCA increased from 24.9 to 28.3 in stage I disease and from 20.9 to 25.9 in stage II disease. Sleep and symptom scores also improved; there was no placebo or untreated group.

MoCA score, mean ± SD · Stage I: 24.9 ± 3.78 → 26.5 ± 2.77 → 28.3 ± 2.18; stage II: 20.9 ± 4.79 → 24.6 ± 3.64 → 25.9 ± 3.88 · Within-stage values; not randomized disease-stage comparison · Baseline → end of treatment → 45-day follow-up

Reported findings and study design

In the 2025 open Picamilon comparison, MoCA increased from 24.9 to 28.3 in stage I disease and from 20.9 to 25.9 in stage II disease. Sleep and symptom scores also improved; there was no placebo or untreated group.

100 enrolled: stage I 50 (oral 25; sequential injection/oral 25), stage II 50. Efficacy analyzed in 94 completers; all 100 in safety. Treatment 60 days (I) or 70 days (II); follow-up 45 days later.

Results · Original publisher PDF methods and Tables 3–7, 10 text reviewed; visual table verification and complete Doppler-table transcription remain open
MeasureResultComparison, timing and statistics
MoCA score, mean ± SDStage I: 24.9 ± 3.78 → 26.5 ± 2.77 → 28.3 ± 2.18; stage II: 20.9 ± 4.79 → 24.6 ± 3.64 → 25.9 ± 3.88Within-stage values; not randomized disease-stage comparison · Baseline → end of treatment → 45-day follow-up
Sleep score, mean ± SDStage I: 19.7 ± 3.77 → 22.7 ± 3.46 → 24.3 ± 3.06; stage II: 18.5 ± 4.01 → 21.8 ± 3.61 → 22.8 ± 3.01Levin subjective questionnaire; higher is better · Same visits
Adverse events4/50 stage I; 4/50 stage II; none serious or causing discontinuationAll 100 enrolled patients in safety analysis · Treatment period
Attrition6/100 did not complete; efficacy used 94 completersWithdrawals reported unrelated to adverse reactions
Cognition, autonomic symptoms, neurological symptoms and sleep — Tables 3–6
Cognition, autonomic symptoms, neurological symptoms and sleep — Tables 3–6
Measure / groupBaseline mean (SD)End-treatment mean (SD)Follow-up mean (SD)Within-group tests
MoCA · stage I24.9 (3.78)26.5 (2.77)28.3 (2.18)baseline→end p=0.022; end→follow-up p<0.0001
MoCA · stage I oral23.8 (4.44)25.8 (3.37)Not separately listedp=0.065
MoCA · stage I sequential26.1 (2.9)27.2 (1.73)Not separately listedp=0.161
MoCA · stage II20.9 (4.79)24.6 (3.64)25.9 (3.88)p<0.0001; p=0.0006
Vein autonomic scale · I26.7 (14.0)17.3 (12.2)Not measuredp<0.0001
Vein scale · I oral29 (14.9)19.2 (12.3)Not measuredp=0.0004
Vein scale · I sequential24.1 (12.9)15.2 (12)Not measuredp=0.007
Vein scale · II25.3 (13.1)18.3 (15.2)Not measuredp=0.0014
Fedin neurological scale · I11.9 (8.3)6 (6.1)2.77 (4.43)p<0.0001; p<0.0001
Fedin · I oral12.4 (8.12)5.61 (5.12)Not separately listedp=0.0006
Fedin · I sequential11.3 (8.65)6.43 (7.12)Not separately listedp=0.004
Fedin · II17.4 (9.34)8.06 (6.84)5.31 (5.71)p<0.0001; p=0.0002
Levin sleep · I19.7 (3.77)22.7 (3.46)24.3 (3.06)p<0.0001; p=0.0002
Levin sleep · I oral20.0 (4.37)23.7 (3.72)Not separately listedbaseline→end p=0.0026
Levin sleep · I sequential19.3 (3.04)21.5 (2.80)Not separately listedp=0.0051
Levin sleep · II18.5 (4.01)21.8 (3.61)22.8 (3.01)p<0.0001; p=0.009

Tables transcribed from the publisher PDF text, printed pp.103–105; visual page inspection unavailable. Stage I visit 2 sleep: 20.7 (3.19), oral 20.9 (3.63), sequential 20.4 (2.69); stage II 19.3 (4.05). MoCA/Levin higher is better; Vein/Fedin lower is better. Subgroup MoCA changes were not significant.

Arginine biomarkers — original Table 10
Arginine biomarkers — original Table 10
Measure / stageBaseline median (Q1; Q3)End-treatment median (Q1; Q3)Paired p
ADMA · I (n=37)159 (146; 167)135 (108; 157)0.001
SDMA · I179 (163; 212)179 (129; 199)0.104
ADMA/MMA · I14.5 (13.4; 15.3)12 (11.1; 12.4)<0.001
(ADMA+SDMA)/MMA · I31.4 (28.3; 32.8)26.3 (23.4; 29.6)<0.001
SDMA/MMA · I17.3 (13.9; 18)14.2 (12.2; 17.4)0.002
ADMA · II (n=42)167 (148.5; 177)138 (115.5; 152)<0.001
SDMA · II195 (173; 234)186 (148.5; 233)0.037
ADMA/MMA · II14.3 (13.15; 15.3)11.2 (10.85; 12)<0.001
(ADMA+SDMA)/MMA · II33.3 (28.65; 35.8)26.4 (23.2; 31.5)<0.001
SDMA/MMA · II18.1 (14.9; 20.25)15.7 (12.15; 19.25)0.002

Publisher PDF text, printed p.106. ADMA/SDMA concentrations in ng/mL; ratios unitless. Biomarker subset 79, not the full 100. Stage I SDMA did not significantly change. Other vascular tables remain to be visually checked before full transcription.

This paper may overlap with the 2024 Picamilon reports; their participants must not be added as independent cohorts. Active-treatment improvements and blood markers do not establish prevention of stroke or cardiovascular events.

Source for these results ↗ · Reviewed 2026-11-01

Study limitations and source details

Study limitations

  • No untreated or placebo group.
  • Shared investigators, protocols and cohort characteristics suggest possible overlap with the 2024 reports; this is an inference, not confirmed participant identity.
  • The three reports list 44, 50 and 100 participants. The extent of overlap is unknown.

Related publications may describe some of the same participants or experiments.

Source details

Publisher HTML article

Original publisher PDF methods and Tables 3–7, 10 text reviewed; visual table verification and complete Doppler-table transcription remain open

Methods and results

Sources checked

Citation

Uncontrolled human reportFull text available

A. B. Danilov, N. N. Shindryaeva, I. V. Borodulina, T. D. Lunev. Picamilon in stage I and II chronic cerebral ischemia: open comparative study Consilium Medicum. 2025;27(2)

Study source ↗ · DOI 10.26442/20751753.2025.2.203195 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards